Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market (3rd Edition), 2019-2030
Given the invasive and cost-intensive nature of tissue biopsies, there is a significant unmet need for safer and more patient-friendly cancer diagnostics that are capable of offering highly accurate, and actionable insights related to the disease
By: Roots Analysis
Key Market Insights
Close to 300 liquid biopsy-based diagnostics are currently available / under development
Nearly 60% such solutions are available for commercial use, while the rest are either available for research purposes only or under development. Presently, majority of these tests are being developed for the isolation and analysis of cell-free DNA (cfDNA); other popular tumor markers analyzed via this method include circulating tumor DNA (ctDNA), circulating tumor cells (CTCs) and exosomes.
North America is currently a hub of diagnostics development activity; over 50% of developers are based in this region
Recent reports indicate that there are 70 small-sized companies / start-ups, 39 mid-sized players and 6 large and very large business entities based in this part of the world.
USD 3+ billion was invested by both private and public investors, between 2015 and 2019
More than USD 2 billion was raised through venture capital financing alone, representing nearly 80% of the total capital raised. It is worth highlighting that GRAIL raised a total of USD 900 million in its series B financing round.
Partnership activity in this domain has increased at an annualized rate of 74%
In fact, around 80% of the deals reported in the study were established post 2016; the maximum partnership activity was observed in 2018. Majority of these agreements (80+) were observed to be either distribution & supply agreements and R&D agreements.
Currently, tests intended for patient monitoring have captured more than 60% of the overall market share
Given the challenges related to repeatedly performing invasive biopsies, liquid biopsy is expected to be widely adopted for patient monitoring purposes. However, ongoing efforts to address the high unmet need for early cancer detection are likely to result in an increase in the share of early diagnosis-focused tests, in the foreseen future.
For additional details, please visit
+1 (415) 800 3415
+44 (122) 391 1091